Tisagenlecleucel’s approval set a precedent for the integration of CAR T cell technologies in oncology, highlighting the potent efficacy of CD19-targeted immunotherapies in achieving durable remissions. Subsequent approvals followed, extending the reach of CAR T cells to include adult patients with various B cell malignancies, and spurring interest in expanding this modality to malignancies beyond the B lineage. However, despite these promising advancements, progress in developing additional CAR T cell therapies for other pediatric malignancies has been comparatively more limited. The complex biology of diseases such as acute myeloid leukemia (AML), T cell acute lymphoblastic leukemia, and solid tumors presents significant challenges to CAR T cell design and implementation.

One of the foremost hurdles in broadening CAR T cell applications lies in the heterogeneous antigen expression profiles among diverse malignancies, which undermines the specificity and persistence of engineered T cells. Unlike the relatively uniform and highly specific expression of CD19 on B lineage cells, AML and T cell leukemias demonstrate antigenic variability and overlap with normal hematopoietic cells, raising issues of on-target off-tumor toxicity. Furthermore, solid tumors and central nervous system malignancies pose formidable barriers including antigen heterogeneity, limited T cell infiltration, immunosuppressive tumor microenvironments, and physical obstacles such as the blood-brain barrier. These challenges have stalled the development of effective and safe CAR T products in these contexts, despite active preclinical and early clinical investigations.

The initial clinical trials and subsequent commercialization of CD19-targeted CAR T cells have laid the groundwork for understanding both the potential and limitations of this modality. Early experiences underscored critical aspects of safety management, such as the mitigation of cytokine release syndrome and neurotoxicity, which are unique to CAR T therapies. These toxicities necessitated the establishment of specialized treatment centers and rigorous monitoring protocols, shaping the infrastructure required to deliver these complex biologics safely. Additionally, insights into CAR T cell manufacturing, logistics, and product quality have refined approaches, although challenges related to scalability and cost remain.

In the pediatric and young-adult population, these therapies have not only offered a lifeline for patients with relapsed or refractory disease but have also demonstrated the feasibility of integrating gene-modified cell therapies into treatment pathways. Importantly, real-world data have revealed survival benefits unparalleled by conventional therapies, promoting earlier use of CAR T cells in treatment algorithms. Nevertheless, access to these life-saving treatments is constrained by multiple factors, including manufacturing bottlenecks, reimbursement issues, and disparities in care delivery, particularly across geographic and socioeconomic divides.

Current research efforts are intensifying the quest to push CAR T cell therapy beyond its established boundaries. Strategies to overcome antigen escape include the development of CAR T cells targeting multiple antigens simultaneously or sequentially, enhancing durability and reducing relapse. Moreover, refinement of CAR constructs to improve T cell fitness, trafficking, and resistance to tumor-mediated immunosuppression holds promise for extending efficacy to solid tumors and CNS malignancies. Gene editing technologies, such as CRISPR, are enabling the creation of allogeneic “off-the-shelf” CAR T cells, which could alleviate the manufacturing delays inherent in autologous therapies.

In parallel, the field is exploring combinatorial immunotherapies that incorporate CAR T cells with checkpoint inhibitors, oncolytic viruses, or other modulators of the tumor microenvironment to amplify anti-tumor responses. These combination approaches aim to address the multifactorial mechanisms of immune escape and tumor resistance that single-agent CAR T therapies cannot fully overcome. Clinical trial designs are evolving to test these novel paradigms, including adaptive trial frameworks that facilitate rapid iteration based on emerging data.

Safety considerations remain paramount as CAR T cells navigate increasingly complex biological environments. The potential for off-target effects, prolonged immunosuppression, and unforeseen toxicities necessitates ongoing surveillance and development of safety switches or “suicide” genes within CAR constructs. Additionally, understanding the long-term effects of CAR T cell persistence and integration is crucial, especially in pediatric patients who may face lifelong consequences.

From a clinical perspective, decision-making about the optimal use of CAR T cells involves a nuanced assessment of disease features, patient-specific factors, and alternative therapies. For instance, immunotherapies such as bispecific T cell engagers and antibody-drug conjugates are providing alternative or complementary options that may influence sequencing or combination strategies. Personalized approaches that integrate genomic, immunophenotypic, and microenvironmental data are anticipated to enhance patient selection and outcome prediction.

The economic implications of CAR T cell therapies are significant, with high upfront costs juxtaposed against potential long-term survival benefits and quality-of-life improvements. Health economics and policy frameworks must evolve to address reimbursement models, equitable access, and sustainable integration into healthcare systems worldwide. Furthermore, educational initiatives targeting clinicians, patients, and families are essential to optimize expectations and engagement in this rapidly advancing field.

As the CAR T cell field matures, researchers are gaining a deeper appreciation of the interplay between engineered cells and host immunity. Advances in single-cell analyses and systems immunology are elucidating mechanisms of resistance, immune modulation, and toxicity, guiding next-generation CAR designs. Integration of artificial intelligence and machine learning is accelerating the identification of novel targets and the optimization of manufacturing processes.

In summary, CAR T cell therapy represents a cornerstone of precision immuno-oncology for pediatric, adolescent, and young adult cancer patients. While the success of CD19-directed CAR T cells is unquestionable, the field is poised for transformative growth through innovation that addresses existing limitations and expands therapeutic horizons. Collaborative efforts among scientists, clinicians, regulatory bodies, industry, and patient advocates are essential to realize the full potential of CAR T cells and to democratize access globally.

The evolution of CAR T cell therapy encapsulates a paradigm shift in cancer treatment, one that harnesses the power of the immune system with unprecedented specificity and adaptability. Continuing research endeavors promise to unlock new frontiers, bringing hope to patients facing some of the most challenging malignancies of childhood and early adulthood. The future of CAR T cell therapy is not merely one of incremental improvements but of revolutionary breakthroughs that could redefine oncologic outcomes across diverse disease landscapes.

Subject of Research: CAR T cell therapy in pediatric, adolescent, and young adult cancer patients, focusing on applications, challenges, safety, access, and future developments.

Article Title: The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.

Article References:
Schultz, L., McNerney, K., Lamble, A.J. et al. The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer. Nat Rev Clin Oncol (2026). https://doi.org/10.1038/s41571-025-01115-w

Image Credits: AI Generated

Standard frontline therapies have improved survival rates; however, patients who experience relapse or are refractory to conventional treatments confront a grim prognosis. A breakthrough in recent years has been the introduction of immunotherapies targeting the CD19 antigen—a surface protein ubiquitously expressed on B-ALL cells. CAR-T (chimeric antigen receptor T-cell) therapies engineered to recognize CD19 have revolutionized treatment paradigms, demonstrating remarkable initial response rates. Yet, clinical outcomes remain unsatisfactory for a substantial subset of patients, with nearly half relapsing primarily due to cancer cells orchestrating immune evasion via downregulation or loss of CD19 expression.

Addressing this mechanism of immune escape, researchers from the Josep Carreras Leukaemia Research Institute and Hospital 12 de Octubre – CNIO undertook pioneering experimental work to develop a dual-targeted CAR-T cell therapy. Led by Dr. Pablo Menéndez, Dr. Clara Bueno, and Dr. Luis Álvarez Vallina, the team designed genetically modified T-cells capable of simultaneously targeting two distinct B-ALL surface antigens: CD19 and CD22. CD22 serves as an alternative, non-overlapping marker consistently present on leukemic blasts, presenting a rational target to complement CD19.

The innovation lies in the sophisticated engineering of the CAR-T cells to combine two complementary strategies within a single therapeutic agent. These CAR-T cells deploy a conventional chimeric antigen receptor construct directed against CD22, facilitating direct cytotoxic engagement of leukemic populations expressing this marker. Simultaneously, these engineered T-cells secrete a bispecific T-cell engager (BiTE) molecule focused on recruiting endogenous T-cells—irrespective of their CAR-T status—towards the CD19 antigen on the tumor cells. This dual mechanism effectively "double-dips" the immune response, enhancing both precision and breadth of leukemic cell targeting.

This approach leverages the unique strengths of both CAR-T technology and bispecific antibody therapy. CAR-T cells offer the advantage of long-lived persistence and sustained cytotoxicity, capable of trafficking throughout the body to eliminate malignancies. In contrast, bispecific antibodies function as bridges that physically tether cytotoxic T-cells to cancer cells, promoting potent immune synapse formation and rapid tumor cell lysis. By integrating BiTE secretion within CAR-T cells, the therapy amplifies immune activation and recruitment, mitigating the risk of tumor cells escaping immune surveillance through antigen loss variants.

Preclinical in vitro investigations revealed that these dual-targeting CAR-T cells markedly improved leukemic control compared to single-antigen targeting counterparts. The bispecific engagement significantly increased the recruitment and activation of bystander T-cells to CD19-expressing leukemia cells, while the direct CD22 CAR-mediated cytotoxicity ensured clearance of leukemic clones that had escaped CD19 targeting. Importantly, this led to prolonged control of leukemic growth and potential reduction in relapse incidence.

Published in the Journal for ImmunoTherapy of Cancer and co-authored by Javier Arroyo Ródenas and Aïda Falgàs, the study marks a pioneering step towards next-generation CAR-T immunotherapies that circumvent antigen escape mechanisms—one of the most formidable barriers to durable remission in relapsed B-ALL. The researchers emphasize that the bifunctional design could redefine treatment paradigms, offering renewed hope for pediatric patients facing limited options after relapse.

The success of this experimental study underscores the importance of multi-antigen targeting within immuno-oncology, particularly in hematological malignancies where antigen heterogeneity and plasticity fuel therapeutic resistance. By harnessing the endogenous immune system’s full cytotoxic potential and imparting long-term surveillance capacity, these "armored" CAR-T cells embody a strategic advance in precision medicine.

Furthermore, the modular construction of these CAR-T cells facilitates adaptability; the BiTE component secreted could theoretically be re-engineered to target alternative tumor-specific antigens or combined with additional immune-stimulatory molecules. This flexibility paves the way for bespoke immunotherapies tailored to diverse malignancies characterized by complex antigenic landscapes.

This research was made possible through funding by several esteemed institutions, including the European Commission’s ERC program, multiple Spanish governmental bodies, regional funds from the Generalitat de Catalunya and Comunidad de Madrid, as well as private entities dedicated to cancer research. Such robust support reflects the growing recognition that innovative immunotherapy solutions are crucial to addressing unmet clinical needs in childhood cancers.

As this CAR-T and bispecific antibody fusion approach progresses towards clinical translation, its implications extend beyond B-ALL. Similar dual-targeting strategies may be exploited for other refractory hematologic cancers and solid tumors notorious for evading mono-targeted immunotherapies. The future of cancer treatment undoubtedly lies in combinatorial immunotherapeutic designs that enhance efficacy while mitigating resistance.

Overall, this study presents a timely, technologically sophisticated immunotherapeutic platform with the potential to transform leukemia care. Its dual targeting mechanism heralds a paradigm shift toward more resilient, lasting remissions for children afflicted with one of the most prevalent and deadly pediatric cancers. Ongoing research and eventual clinical trials will determine its full impact on patient survival and quality of life worldwide.

Subject of Research: Cells

Article Title: CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression

News Publication Date: 30-Apr-2025

Web References:
https://doi.org/10.1136/jitc-2024-009048

References:
Arroyo-Ródenas J, Falgàs A, Díez-Alonso L, et al. “CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression”. Journal for ImmunoTherapy of Cancer. 2025;13:e009048. doi:10.1136/jitc-2024-009048

Image Credits: Josep Carreras Leukaemia Research Institute

Keywords: Immunotherapy, Antibody therapy, Cancer immunotherapy, Antibodies, Leukemia

B-ALL is a pernicious cancer characterized by an overproduction of immature B-cells, a vital component of the immune system responsible for antibody production. These malignant cells proliferate within the bone marrow, crowding out healthy blood cells and disseminating to other organs, including the brain, where they can evade conventional therapies. The disease commonly afflicts children, accounting for about 40% of all childhood cancers, but it also affects adults, in whom treatment outcomes are typically poorer.

Current standard-of-care approaches for B-ALL involve lengthy and intensive chemotherapy protocols spanning over two years, which, while often effective in younger patients, carry profound toxicities. Patients endure severe side effects such as immunosuppression leading to infections, bruising, bleeding, nausea, hair loss, and long-term complications affecting the nervous system, joints, and cardiac function. Alternative therapies like bone marrow transplants and CAR-T cell therapy have emerged but present their own challenges, including severe side effects, high costs, and complex logistics.

In a paper published in Nature Communications, a team led by Dr. Simon Richardson and Professor Brian Huntly has unveiled a promising new strategy employing a combination of two oral agents: venetoclax and inobrodib. Venetoclax, already approved for a related blood malignancy, acute myeloid leukemia (AML), functions by inhibiting the BCL2 protein, a key regulator of apoptosis or programmed cell death in cancerous B-cells. However, venetoclax alone shows inconsistent effectiveness against B-ALL, prompting researchers to explore mechanisms underlying resistance.

Their investigations centered on the CREBBP gene, which when mutated or inactivated, contributes to disease progression and chemotherapy resistance. CREBBP plays a crucial role in cellular metabolism and gene expression regulation. Astonishingly, the team discovered that inactivating CREBBP rewires the fat metabolism pathways within malignant B-cells. This metabolic shift sensitizes cells to death by ferroptosis — a form of programmed cell death distinct from apoptosis. Ferroptosis involves the iron-dependent peroxidation of lipids in cell membranes, which, when unchecked, leads to catastrophic cellular damage and demise.

To exploit this vulnerability, the Cambridge researchers utilized inobrodib, an inhibitor of CREBBP developed by CellCentric, a Cambridge spinout company. Through CREBBP inhibition with inobrodib, the cancer cells undergo metabolic rewiring that diminishes their ability to prevent lipid damage. When combined with venetoclax’s blockade of BCL2, this dual insult induces ferroptotic cell death in B-ALL cells, including those harboring mutations that confer resistance to venetoclax alone.

Experimental models using human and mouse B-ALL cells demonstrated that this combination therapy powerfully eradicated malignant early-stage B-cells. Notably, the therapy maintained effectiveness against genetically resilient leukemia cells, highlighting its potential to overcome existing treatment barriers. Professor Huntly emphasized the significance of these findings, noting that venetoclax and inobrodib have been safely combined in early trials for AML, bolstering hopes for rapid translation into clinical trials for B-ALL patients.

This therapeutic innovation carries several clinical advantages. Because the drugs are administered orally, the treatment paradigm could be less invasive and more convenient than current protocols. Moreover, the selective targeting of cancerous B-cells with this approach suggests fewer off-target effects, potentially sparing patients the debilitating toxicities commonly associated with chemotherapy and immunotherapies like CAR-T cells—the latter of which can irreversibly deplete normal B-cell populations, impairing immune competence.

Dr. Richardson elaborated on the immune implications, explaining that although B-cells are depleted during administration, the body’s capacity to regenerate healthy B-cells should restore immune function post-treatment. This transient effect markedly contrasts with permanent B-cell aplasia seen in CAR-T cell therapies, making venetoclax and inobrodib a potentially safer therapeutic option.

An important economic consideration accompanies this therapeutic prospect. Venetoclax’s patent expiration in the near future is anticipated to reduce its cost substantially through generics, improving accessibility and affordability for patients and healthcare systems alike. Such developments could democratize use and alleviate financial burdens associated with novel cancer therapies.

The urgency for improved B-ALL therapies is underscored by the real-life experience of survivors like Gill Murphy, who endured aggressive chemotherapy and stem cell transplant for her disease. Her story reveals the profound physical and psychological toll of current treatments, including prolonged hospitalizations and enduring side effects such as fatigue, early menopause, and cognitive challenges. Murphy’s testimony provides a poignant backdrop for the pressing need to develop more tolerable and effective treatments.

Cancer researchers have long sought strategies that not only eliminate malignant cells but also minimize collateral damage to patients’ quality of life. The Cambridge team’s discovery of ferroptosis induction via CREBBP inactivation, combined with BCL2 inhibition, represents a breakthrough in this quest. By harnessing the cancer cell’s metabolic liabilities, this approach exploits a previously untapped cell death pathway, broadening therapeutic horizons.

Despite the promising preclinical data, rigorous clinical trials are essential before this dual-drug approach can become standard treatment. The researchers are actively pursuing funding to initiate clinical trials involving adults and teenagers with B-ALL. Success in these trials could herald a new era of cancer treatment that balances efficacy with safety and patient well-being.

Beyond B-ALL, this research might also illuminate the role of ferroptosis in other hematologic malignancies and solid tumors, inspiring novel drug combinations that trigger ferroptotic cell death in resistant cancers. As scientists deepen understanding of cancer metabolism and cell death pathways, such targeted treatments could transform oncological care globally.

In conclusion, the combination of venetoclax and inobrodib leverages cutting-edge insights into genetic mutations and metabolic reprogramming to strike at the heart of B-ALL survival mechanisms. Its promise lies not only in potentially overcoming drug resistance but in offering a gentler, more precise treatment pathway that could improve survival while mitigating the physical and emotional burdens endured by patients. As research progresses, hopes rise for a future where blood cancers like B-ALL are not just treatable but conquered with compassion and precision.

Subject of Research: Animals

Article Title: CREBBP inactivation sensitizes B cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 Inhibition

News Publication Date: 20-May-2025

Web References: 10.1038/s41467-025-59531-6

References: Garcia-Gimenez, A, et al. CREBBP inactivation sensitizes B cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 Inhibition. Nat Comms; 20 May 2025; DOI: 10.1038/s41467-025-59531-6

Keywords: Blood cancer, Leukemia, Cancer

Current research, spearheaded by an international team including experts from the Josep Carreras Leukaemia Research Institute and the Spanish National Cancer Research Center (CNIO), has brought forth a promising new strategy that may help mitigate this issue. The team published their findings in a significant study in the journal Blood, revealing insights into the underlying mechanisms of relapse in B-ALL and proposing a novel intervention that could potentially enhance CAR-T therapy’s effectiveness. The findings emphasize the compelling need to investigate and address the intricate interactions between CAR-T cells and leukemia cells.

CAR-T therapies work by genetically modifying a patient’s own T-cells to express chimeric antigen receptors (CARs) that specifically target leukemia cells. Although the initial responses to CAR-T cell therapy have been encouraging, the phenomenon of tumor relapse continues to pose a formidable challenge. Researchers have turned their attention to the relationship between the cancer cells and the immune cells, uncovering crucial interactions that allow leukemia to evade the energetic assault by the CAR-T cells.

A pivotal discovery from this research was that the relapsed B-ALL cells exhibit remarkably high levels of galectin-9, a protein known to play a role in immune modulation. This excess of galectin-9 creates a safety net for the cancer cells, allowing them to manipulate the body’s immune checkpoints, which serve as off switches for immune activation. Simultaneously, CAR-T cells express elevated levels of TIM-3, a receptor that interacts with galectin-9, effectively leading to an immune response feebly directed against the tumor.

What unfolds in this interaction is somewhat alarming: the galectin-9 and TIM-3 interplay acts like a double-edged sword. On one hand, TIM-3’s role as an immune checkpoint normally aids in the dampening of immune responses after an infection or threat has been addressed. On the other, relapsed leukemia exploits this mechanism to hijack CAR-T cells, forcing them into an inactive state and facilitating their evasion from immune detection. This crucial understanding opens the door to a new line of defense, where blocking this inhibitory signal could rekindle CAR-T activity against the leukemia.

The groundbreaking approach devised by the researchers involved generating a TIM-3 decoy. This soluble variant of the TIM-3 protein aims to disrupt the harmful interaction with galectin-9 without overtly activating or inertializing the CAR-T cells. Instead, it seeks to maintain constant immune activity while effectively shielding CAR-T cells from suppression. In preclinical experiments utilizing genetically modified mice harboring human B-ALL cells, the introduction of CAR-T cells engineered to secrete this TIM-3 decoy demonstrated significant improvements in anti-leukemia efficacy and exhibited a longer duration of active response against the cancer.

As the study progresses through preclinical phases, researchers are optimistic that these findings could pave the way toward developing more advanced CAR-T cell therapies. There’s potential not only for improving treatment outcomes for patients suffering from B-ALL but also for extending the use of CAR-T technology to other types of cancers, particularly solid tumors where similar immune evasion tactics are often employed by malignancies.

The findings of this research hold immense promise in shifting the paradigm of how relapsed B-ALL is treated, urging the scientific community to explore enhanced strategies that bolster CAR-T cell efficiency against aggressive malignancies. Future studies focusing on human clinical trials will be critical to validate these findings and ascertain the practical applicability of the TIM-3 decoy approach in diverse patient populations.

This pioneering research not only illuminates the complexity of the immune-evasive tactics employed by B-ALL leukemia but also underscores the pressing urgency of addressing the relapse phenomenon in CAR-T therapies. It also encourages a broader assessment of immune checkpoint pathways’ roles in cancer biology, opening up plethora of avenues for therapeutic exploration.

Through continued innovation, the hope remains that CAR-T therapies will one day achieve not merely temporary remission but sustained and lasting cures for patients afflicted with B-ALL. The collaborative efforts across diverse institutions indicate a collective commitment to overcoming challenges and achieving better clinical outcomes, propelling cancer therapeutics into a new era characterized by enhanced precision and effectiveness.

Thus, as research evolves and methodologies improve, the dream of harnessing the full potential of the immune system against cancer continues to draw nearer. Such advancements could dramatically reshape the future of oncology, transforming the landscape of how diseases like B-ALL are approached and managed.

Subject of Research: B-cell Acute Lymphoblastic Leukemia
Article Title: A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia
News Publication Date: March 16, 2025
Web References: Doi Reference
References: None available
Image Credits: Amparo Garrido / CNIO

Keywords: B-cell Acute Lymphoblastic Leukemia, CAR-T therapy, immune checkpoint pathways, TIM-3 decoy, galectin-9, leukemia treatment, preclinical research, cancer immunotherapy, relapsed leukemia, cancer biology, engineered T-cells, experimental study.